6-[2-(dimethylamino)propyl]-11H-pyrido[3,2-c][1,5]benzodiazepin-5-one;hydron;chloride | 14559-79-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 6-[2-(dimethylamino)propyl]-11H-pyrido[3,2-c][1,5]benzodiazepin-5-one;hydron;chloride
• CAS: 14559-79-6
• 化学式: C17H21ClN4O
• 分子量: 332.8
• InChiKey: DNZVNKSQOUOBOY-UHFFFAOYSA-N

物化性质

• 熔点：
  235°

计算性质

• 辛醇/水分配系数(LogP)：
  3.16
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  48.5
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  6.1(b)

文献信息

• Room temperature stable aqueous liquid pharmaceutical composition
  申请人：Clemente Emmett

  公开号：US20060013834A1

  公开（公告）日：2006-01-19

  A liquid pharmaceutical composition is contemplated that comprises a pharmaceutically effective amount of a drug dissolved or dispersed in an aqueous medium. The aqueous medium consists essentially of water, about 3% to about 10% w/v polyvinylpyrrolidone, about 60% to about 75% w/v of C 3 -C 6 polyol that includes more than 55% w/v of a non-reducing disaccharide, trisaccharide or tetrasaccharide such as sucrose, optionally about 0.01% to about 0.5% w/v of a glycyrrhetic acid, glycyrrhizinate derivative or salt thereof, and one or more flavorants, and preferably includes one or more preservatives. The liquid composition is room temperature stable, and may have a pleasant taste.

  一种液体药物组合物包括溶解或分散在水性介质中的药用有效量的药物。水介质主要由水、约 3% 至约 10% w/v 的聚乙烯吡咯烷酮、约 60% 至约 75% w/v 的 C 3 -C 6 多元醇，其中包括 55% w/v 以上的非还原性二糖、三糖或四糖，如蔗糖，可选约 0.01% 至约 0.5% w/v 的甘草酸、甘草酸盐衍生物或其盐，以及一种或多种调味剂，最好还包括一种或多种防腐剂。液体组合物在室温下稳定，并可能具有令人愉悦的口感。
• MODIFIED RELEASE MULTIPLE-UNITS COMPOSITIONS OF NON-STEROID ANTI-INFLAMMATORY DRUG SUBSTANCES (NSAIDs)
  申请人：NYCOMED DANMARK A/S

  公开号：EP1017370A1

  公开（公告）日：2000-07-12
• QUICK RELEASE PHARMACEUTICAL COMPOSITIONS OF DRUG SUBSTANCES
  申请人：NYCOMED DANMARK A/S

  公开号：EP1109534A1

  公开（公告）日：2001-06-27
• ROOM TEMPERATURE STABLE AQUEOUS LIQUID PHARMACEUTICAL COMPOSITION
  申请人：Biomarin Pharmaceutical Inc.

  公开号：EP1850854A1

  公开（公告）日：2007-11-07
• Quick release pharmaceutical compositions of drug substances
  申请人：Bertelsen Egon Poul

  公开号：US20050147668A1

  公开（公告）日：2005-07-07

  The present invention relates to an oral modified release pharmaceutical composition for the administration of a therapeutically and/or prophylactically effective amount of an active substance (a drug substance) to obtain a relatively fast or quick onset of the therapeutic and/or prophylactic effect The drug substances contained in a modified release pharmaceutical composition according to the invention are suitably a drug substance which has a very low solubitity under acidic conditions, i.e. under conditions similar to those present in the stomach and/or drug substances which have a pK a value below about 5.5 such as in a range of from about 4 to about 5. The composition is based on a powder comprising a therapeutically and/or prophylactically active substance and has such a particle size that when the powder is subjected to a sieve analysis, then at least about 90% w/w of the particles passes through sieves 180 μm and the powder is contacted with an aqueous medium to form a particulate composition, which has such a particle size that when the particulate composition is subjected to a sieve analysis, then at least about 50% w/w of the particles passes through sieve 180 μm. Furthermore, the composition, when tested in accordance with the dissolution method (1) defined herein employing 0.07 N hydrochloric acid as dissolution medium, releases at least about 50% w/w of the active substance within the first 20 min of the test